These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24457263)

  • 1. Limitations of body surface area-based activity calculation for radioembolization of hepatic metastases in colorectal cancer.
    Lam MG; Louie JD; Abdelmaksoud MH; Fisher GA; Cho-Phan CD; Sze DY
    J Vasc Interv Radiol; 2014 Jul; 25(7):1085-93. PubMed ID: 24457263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
    Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
    Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.
    Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA
    Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary?
    McCann JW; Larkin AM; Martino LJ; Eschelman DJ; Gonsalves CF; Brown DB
    J Vasc Interv Radiol; 2012 May; 23(5):661-7. PubMed ID: 22440592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-Response and Dose-Toxicity Relationships for Glass
    Alsultan AA; van Roekel C; Barentsz MW; Smits MLJ; Kunnen B; Koopman M; Braat AJAT; Bruijnen RCG; de Keizer B; Lam MGEH
    J Nucl Med; 2021 Nov; 62(11):1616-1623. PubMed ID: 33741643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
    Young JY; Rhee TK; Atassi B; Gates VL; Kulik L; Mulcahy MF; Larson AC; Ryu RK; Sato KT; Lewandowski RJ; Omary RA; Salem R
    J Vasc Interv Radiol; 2007 Nov; 18(11):1375-82. PubMed ID: 18003987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
    Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
    Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A; Haug AR; Zech CJ; Schaller UC
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
    Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
    J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
    Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
    Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization following Liver Resection: Safety and Dosing Considerations.
    Kessler J; Lewis A; Gagandeep S; Ituarte PH; Park JJ
    J Vasc Interv Radiol; 2016 Jan; 27(1):46-51. PubMed ID: 26552498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic Activity Distribution in Radioembolization with Yttrium-90-Labeled Resin Microspheres Using the Body Surface Area Method--A Less than Perfect Model.
    Grosser OS; Ulrich G; Furth C; Pech M; Ricke J; Amthauer H; Ruf J
    J Vasc Interv Radiol; 2015 Nov; 26(11):1615-21. PubMed ID: 26321017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.